Hofer M, Pospísil M, Holá J, Vacek A, Streitová D, Znojil V
Laboratory of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Brno, Czech Republic.
Radiat Res. 2008 Nov;170(5):566-71. doi: 10.1667/RR1387.1.
Meloxicam, a selective inhibitor of cyclooxygenase 2, was tested to determine its ability to modulate hematopoiesis and to influence survival of mid-lethally gamma-irradiated mice. A single dose of meloxicam (20 mg/kg) administered to mice intraperitoneally 1 h before irradiation was shown to enhance serum levels of granulocyte colony-stimulating factor (G-CSF) during the first 24 h after irradiation, to elevate numbers of granulocytic precursor cells in bone marrow and granulocyte counts in peripheral blood on day 10 after irradiation, and to increase 30-day survival of these mice. The results provide new evidence for the protective ability of meloxicam administration to mice irradiated with mid-lethal doses and contribute to the understanding of the mechanisms of this meloxicam action by drawing attention to the possible role of increased endogenous G-CSF production.
美洛昔康是一种环氧化酶2的选择性抑制剂，对其调节造血功能以及影响经中等剂量γ射线照射小鼠存活率的能力进行了测试。在照射前1小时给小鼠腹腔注射单剂量美洛昔康（20毫克/千克），结果显示，照射后的头24小时内，血清粒细胞集落刺激因子（G-CSF）水平升高，照射后第10天，骨髓中粒细胞前体细胞数量增加，外周血粒细胞计数升高，并且这些小鼠的30天存活率提高。这些结果为美洛昔康对中等致死剂量照射小鼠的保护能力提供了新证据，通过关注内源性G-CSF产生增加的可能作用，有助于理解美洛昔康的作用机制。
